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Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA 
vaccine-elicited antibodies
 
Dami A. Collier1,2,3,18, Anna De Marco4,18, Isabella A.T.M. Ferreira1,2,18, Bo Meng1,2,18, 
Rawlings Datir1,2,3,18, Alexandra C. Walls5, Steven A. Kemp S1,2,3, Jessica Bassi4, Dora Pinto4, 
Chiara Silacci Fregni4, Siro Bianchi4, M. Alejandra Tortorici5, John Bowen5, Katja Culap4, 
Stefano Jaconi4, Elisabetta Cameroni4, Gyorgy Snell6, Matteo S. Pizzuto4, 
Alessandra Franzetti Pellanda7, Christian Garzoni7, Agostino Riva8, The CITIID-NIHR 
BioResource COVID-19 Collaboration*, Anne Elmer9, Nathalie Kingston10, Barbara Graves10, 
Laura E. McCoy3, Kenneth G. C. Smith1,2, John R. Bradley2,10, Nigel Temperton11,  
L. Lourdes Ceron-Gutierrez12, Gabriela Barcenas-Morales12,13, The COVID-19 Genomics UK 
(COG-UK) consortium, William Harvey14, Herbert W. Virgin6, Antonio Lanzavecchia4, 
Luca Piccoli4, Rainer Doffinger12,15, Mark Wills2, David Veesler5, Davide Corti4,18 ✉ & 
Ravindra K. Gupta1,2,15,16,17,18 ✉
SARS-CoV-2 transmission is uncontrolled in many parts of the world, compounded in 
some areas by higher transmission potential of the B1.1.7 variant1 now reported in 94 
countries. It is unclear whether responses to SARS-CoV-2 vaccines based on the 
prototypic strain will be impacted by mutations found in B.1.1.7. Here we assessed 
immune responses following vaccination with mRNA-based vaccine BNT162b22. We 
measured neutralising antibody responses following first and second immunisations 
using pseudoviruses expressing the wild-type Spike protein or the 8 amino acid 
mutations found in the B.1.1.7 spike protein. The vaccine sera exhibited a broad range 
of neutralising titres against the wild-type pseudoviruses that were modestly reduced 
against B.1.1.7 variant. This reduction was also evident in sera from some convalescent 
patients. Decreased B.1.1.7 neutralisation was also observed with monoclonal 
antibodies targeting the N-terminal domain (9 out of 10), the RBM (5 out of 31), but not 
in RBD neutralising mAbs binding outside the RBM. Introduction of the E484K 
mutation in a B.1.1.7 background to reflect a newly emergent Variant of Concern (VOC 
202102/02) led to a more substantial loss of neutralising activity by vaccine-elicited 
antibodies and mAbs (19 out of 31) over that conferred by the B.1.1.7 mutations alone. 
E484K emergence on a B.1.1.7 background represents a threat to the vaccine BNT162b.
The mRNA BNT162b2 vaccine encodes the full-length trimerised S 
protein of SARS CoV-22, designed against the Wuhan-1 isolate. Concerns 
have been raised as to whether vaccines will be effective against newly 
emergent SARS-CoV-2 variants, such as B.1.1.7 (N501Y.V1). In clinical 
studies of BNT162b2, GMT rose after first dose with high levels of pro-
tection against infection and severe disease after the second dose3.
Results
Thirty seven participants had received the first dose of the BNT162b2 
mRNA vaccine three weeks prior to blood draw for serum and peripheral 
blood monocnulear cells (PBMC) collection. Median age was 62 years 
(IQR 47-84) and 35% were female. Twenty-one of these participants also 
had a blood draw 3 weeks after receiving the second dose of BNT162b2 
mRNA vaccine. Serum IgG titres to Nucleocapsid (N) protein, S and the 
S receptor binding domain (RBD) were assayed (Extended Data Fig. 1a).
Using lentiviral pseudotyping we studied WT (wild type bearing 
D614G) and mutant B.1.1.7 S proteins (Fig. 1a) in order to measure neu-
tralisation activity of vaccine-elicited sera. The vaccine sera exhibited 
a range of inhibitory dilutions giving 50% neutralisation (ID50) (Fig. 1b, 
c). The GMT against wild type (WT) following the second dose of vaccine 
was substantially higher than after the first dose (318 vs 77) (Fig. 1b–e). 
There was correlation between total Spike IgG titres and serum neutrali-
sation titres (Extended Data Fig. 1b). A broad range of T cell responses 
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was measured by IFN gamma FluoroSpot against SARS-CoV-2 peptides 
in vaccinees after first dose. These cellular responses did not correlate 
with serum neutralisation titres or IgG S antibody titres (Extended 
Data Fig. 1c-d).
We then generated mutated pseudoviruses carrying S protein with 
mutations N501Y, A570D and the H69/V70 deletion. We observed a small 
increase in the ability of sera from vaccinees and convalescent individu-
als to inhibit this triple mutant virus (Extended Data Fig. 2a, b, 2c). We 
next completed the full set of eight mutations in the S protein present in 
B.1.1.7 variant (Fig. 1a). 20/29 of those with neutralisation activity after 
first dose showed evidence of a reduction in B.1.1.7 neutralisation titres 
(Fig. 1b, c, Extended Data Fig. 3), with mean fold change of 3.2 (SD 5.7). 
Following the second dose, GMT was markedly increased compared with 
first dose titres, with mean fold change 1.9 (SD 0.9) (Fig. 1d, e). Amongst 
sera from 27 recovered individuals, the GMT at 50% neutralisation was 
1334 for WT, significantly higher than post second dose vaccination 
(Fig. 1f, g). The fold change in ID50 for neutralisation of B.1.1.7 versus 
wild type (D614G) was 4.5 (Fig. 1f, g and Extended Data Fig. 4).
The E484K substitution (Fig. 2a) has been reported as an escape 
mutation for several monoclonal antibodies4, and is present in the 
B.1.351 (501Y.V2) and P.1 (501Y.V3) lineages. As of 11th of February 2021, 
thirty B.1.1.7 sequences also had the E484K substitution (Fig. 2c). Phy-
logenetic analysis suggests that there have been multiple independent 
acquisitions, with one lineage appearing to expand over time, indicating 
active transmission (Fig. 2b). This has resulted in Public Health England 
naming this as a variant of concern (VOC 202102/02)5. We therefore gen-
erated pseudoviruses bearing B.1.1.7 spike mutations with or without 
additional E484K and tested these against sera obtained after first and 
second dose mRNA vaccine as well as against convalescent sera. Follow-
ing second dose, we observed a significant loss of neutralising activity 
for the pseudovirus with B.1.1.7 spike mutations and E484K (Fig. 3d, e). 
The mean fold change for the E484K B.1.1.7 Spike was 6.7 compared to 
1.9 for B.1.1.7, relative to WT (Fig. 3a–c, Extended Data Fig. 5). Similarly 
when we tested a panel of convalescent sera with a range of neutralisa-
tion titres (Fig. 1f, g, Extended Data Fig. 5), we observed additional loss 
of activity against the mutant B.1.1.7 spike with E484K, with fold change 
of 11.4 relative to WT (Fig. 3f, g, Extended Data Fig. 5).
B.1.1.7 monoclonal antibody sensitivity
We tested 60 mAbs isolated from 15 individuals that recovered from 
SARS-CoV-2 infection in early 2020 with an in-vitro pseudotyped neutral-
ization assay against B.1.1.7 spike (Supplementary Table 1). 20 out of 60 
(33.3%) mAbs showed a greater than 2-fold loss of neutralising activity 
of B.1.1.7 variant compared to WT SARS-CoV-2 (Fig. 4a, b and Extended 
Data Fig. 6). B.1.1.7 mutant virus fully escaped neutralization by 8 out of 
10 NTD-targeting mAbs (80%) (Fig. 4c). Of the 31 RBM-targeting mAbs, 
5 (16.1%) showed more than 100-fold decrease in B.1.1.7 neutraliza-
tion, and additional 6 mAbs (19.4%) had a partial 2-to-10-fold reduction 
(Fig. 4d). Finally, all RBD-specific non-RBM-targeting mAbs tested fully 
retained B.1.1.7 neutralising activity (Fig. 4e).
To address the role of B.1.1.7 N501Y mutation in the neutralization 
escape from RBM-specific antibodies, we tested the binding of 50 
RBD-specific mAbs to WT and N501Y mutant RBD by biolayer inter-
ferometry (Fig. 4f and Extended Data Fig. 7). The 5 RBM-specific mAbs 
that failed to neutralize B.1.1.7 variant (Fig. 4d) showed a complete 
loss of binding to N501Y RBD mutant (Fig. 4g, h), demonstrating a role 
for this mutation as an escape mechanism for certain RBM-targeting 
mAbs.
To assess the effect of E484K on this panel of mAbs we generated a 
SARS-CoV-2 pseudotype carrying the K417N, E484K and N501Y muta-
tions (TM). The inclusion of the K417N substitution was prompted by 
the observation that substitutions at this position have been found in 5 
sequences from recent viral isolates within the B.1.1.7 lineage (K417 to N, 
E or R). This is in keeping with convergent evolution of the virus towards 
an RBD with N501Y, E484K and K417N/T as evidenced by B.1.351 and P.1 
lineages. Importantly, mutations at K417 are reported to escape neutral-
ization from mAbs, including the recently approved mAb LY-CoV0164,6. 
Out of the 60 mAbs tested, 20 (33.3%) showed >10 fold loss of neutralis-
ing activity of TM mutant compared to WT SARS-CoV-2 (Fig. 4a, b and 
Extended Data Fig. 6), and of these 19 are RBM-specific mAbs. As above, 
we addressed the role of E484K mutation in escape from RBM-specific 
antibodies, by testing the binding of 50 RBD-specific mAbs to WT and 
E484K mutant RBD by biolayer interferometry (Fig. 4f and Extended 
Data Fig. 8). Out of the 19 RBM-specific mAbs that showed reduced or 
loss of neutralization of TM mutant (Fig. 4d), 16 showed a complete or 
partial loss of binding to E484K RBD mutant (Fig. 4g, h), consistent with 
findings that E484K is an important viral escape mutation7,8,39. Three 
of these 16 mAbs also lost binding to an RBD carrying N501Y, indicat-
ing that a fraction of RBM antibodies are sensitive to both N501Y and 
E484K mutations. Similarly, 3 of the 19 mAbs that lost neutralization 
of TM mutant (S2D8, S2H7 and S2X128) were previously shown to lose 
binding and neutralization to the K417V mutant, and here shown to be 
sensitive to either N501Y or E484K mutations.
B.1.1.7 RBD binding to ACE2
Using biolayer interferometry, we found that ACE2 bound to the B.1.1.7 
RBD with an affinity of 22 nM compared to 133 nM for the WT RBD 
(Extended Data Fig. 9), in agreement with our previous deep-mutational 
scanning measurements using dimeric ACE29. Although ACE2 bound 
with comparable on-rates to both RBDs, the observed dissociation 
rate constant was slower for B.1.1.7 than for the WT RBD (Extended 
data Table 1). These findings might participate in the efficient ongoing 
transmission of this newly emergent SARS-CoV-2 lineage, and possibly 
reduced opportunity for antibody binding. To understand the impact of 
TM mutations (K417N, E484K and N501Y), we evaluated binding of ACE2 
to the immobilized TM RBD. We determined an ACE2 binding affinity 
of 64 nM for the TM RBD, driven by a faster off-rate than observed for 
the B.1.1.7 RBD but slower than for the WT RBD. We propose that the 
K417N mutation is slightly detrimental to ACE2 binding explaining 
the intermediate affinity determined for the TM RBD compared to 
the B.1.17 and WT RBDs, likely as a result of disrupting the salt bridge 
formed with ACE2 residue D30.
Discussion
Serum neutralising activity is a correlate of protection for other res-
piratory viruses, including influenza10 and respiratory syncytial virus 
where prohylaxis with monoclonal antibodies has been used in at-risk 
groups11,12. Neutralising antibody titres appeared to be highly correlated 
with vaccine protection against SARS-CoV-2 rechallenge in non-human 
primates13,14.
This study reports on the neutralisation by sera collected after both 
the first and second doses of the BNT162b2 vaccine. The participants of 
this study were older adults, in line with the targeting of this age group 
in the initial rollout of the vaccination campaign in the UK. We demon-
strated that a pseudovirus bearing S protein with the full set of mutations 
present in the B.1.1.7 variant did result in small reduction in neutralisa-
tion by sera from vaccinees that was more marked following the first 
dose than the second dose. This could be related to increased breadth/
potency/concentration of antibodies following the boost dose. Other 
studies have reported a small reduction of neutralisation against the 
B.1.1.7 variant from individuals vaccinated with two doses of BNT162b215 
and mRNA-127316. The reduced neutralising activity observed with poly-
clonal antibodies elicited by mRNA vaccines observed in this study is 
further supported by the loss of neutralising activity observed with 
human mAbs directed to both RBD and, to a major extent, to NTD.
Multiple variants, including the 501Y.V2 and B.1.1.7 lineages, har-



























are located in a site of vulnerability that is targeted by all known 
NTD-specific neutralising antibodies17,18. The role of NTD-specific neu-
tralising antibodies might be under-estimated, in part by the use of neu-
tralization assays based on target cells over-expressing ACE2 receptors. 
NTD-specific mAbs were suggested to interfere with viral entry based 
on other accessory receptors, such as DC-SIGN and L-SIGN19, and their 
neutralization potency was found to be dependent on different in vitro 
culture conditions17. The observation that 9 out of 10 NTD-specific 
neutralising antibodies failed to show a complete or near-complete 
loss of neutralising activity against B.1.1.7 indicates that this new variant 
may have also evolved to escape from this class of antibodies, that may 
have a yet unrecognized role in protective immunity. Taken together, 
the presence of multiple escape mutations in NTD is supportive of 
the hypothesis that this region of the spike, in addition to RBM, is also 
under immune pressure.
Worryingly, we have shown that there are multiple B.1.1.7 sequences 
in the UK bearing E484K with early evidence of transmission as well as 
independent aquisitions. We measured further reduction in neutralisa-
tion titres by vaccine sera when E484K was present alongside the B.1.1.7 
S mutations. Wu and co-authors16 have also shown that variants carrying 
the E484K mutation resulted in a 3-to-6 fold reduction in neutralization 
by sera from mRNA-1273 vaccinated individuals. Consistently, in this 
study we found that approximately 50% of the RBM mAbs tested lost 
neutralising activity against SARS-CoV-2 carrying E484K. E484K has 
been shown to impact neutralisation by monoclonal antibodies or con-
valescent sera, especially in combination with N501Y and K417N7,20–23.
Vaccines are a key part of a long term strategy to bring SARS-CoV-2 
transmission under control. Our data suggest that vaccine escape to 
current Spike directed vaccines designed against the Wuhan strain will 
be inevitable, particularly given that E484K is emerging independently 
and recurrently on a B.1.1.7 (501Y.V1) background, and given the rapid 
global spread of B.1.1.7. Other major variants with E484K such as 501Y.
V2 and V3 are also spreading regionally. This should be mitigated by 
designing next generation vaccines with mutated S sequences and 
using alternative viral antigens.
Online content
Any methods, additional references, Nature Research reporting sum-
maries, source data, extended data, supplementary information, 
acknowledgements, peer review information; details of author con-
tributions and competing interests; and statements of data and code 
availability are available at https://doi.org/10.1038/s41586-021-03412-7.
1. Volz, E. et al. Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking 
epidemiological and genetic data. medRxiv, 2020.2012.2030.20249034, https://doi.org/ 
10.1101/2020.12.30.20249034 (2021).
2. Mulligan, M. J. et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 
586, 589-593, https://doi.org/10.1038/s41586-020-2639-4 (2020).
3. Polack, F. P. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J 
Med 383, 2603-2615, https://doi.org/10.1056/NEJMoa2034577 (2020).
4. Wang, P. et al. Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody 
Neutralization. bioRxiv, https://doi.org/10.1101/2021.01.25.428137 (2021).
5. PHE. Public Health England statement on Variant of Concern and new Variant Under 
Investigation, <https://www.gov.uk/government/news/
phe-statement-on-variant-of-concern-and-new-variant-under-investigation> (2021).
6. Thomson, E. C. et al. Circulating SARS-CoV-2 spike N439K variants maintain fitness while 
evading antibody-mediated immunity. Cell, https://doi.org/10.1016/j.cell.2021.01.037 
(2021).
7. Greaney, A. J. et al. Comprehensive mapping of mutations to the SARS-CoV-2 
receptor-binding domain that affect recognition by polyclonal human serum antibodies. 
Cell host & microbe, https://doi.org/10.1016/j.chom.2021.02.003 (2021).
8. Andreano, E. et al. SARS-CoV-2 escape <em>in vitro</em> from a highly neutralizing 
COVID-19 convalescent plasma. bioRxiv, 2020.2012.2028.424451, https://doi.
org/10.1101/2020.12.28.424451 (2020).
9. Starr, T. N. et al. Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain 
Reveals Constraints on Folding and ACE2 Binding. Cell 182, 1295-1310 e1220,  
https://doi.org/10.1016/j.cell.2020.08.012 (2020).
10. Verschoor, C. P. et al. Microneutralization assay titres correlate with protection against 
seasonal influenza H1N1 and H3N2 in children. PloS one 10, e0131531, https://doi.org/ 
10.1371/journal.pone.0131531 (2015).
11. Kulkarni, P. S., Hurwitz, J. L., Simoes, E. A. F. & Piedra, P. A. Establishing Correlates of 
Protection for Vaccine Development: Considerations for the Respiratory Syncytial Virus 
Vaccine Field. Viral Immunol 31, 195-203, https://doi.org/10.1089/vim.2017.0147 (2018).
12. Goddard, N. L., Cooke, M. C., Gupta, R. K. & Nguyen-Van-Tam, J. S. Timing of monoclonal 
antibody for seasonal RSV prophylaxis in the United Kingdom. Epidemiol Infect 135,  
159-162, https://doi.org/10.1017/S0950268806006601 (2007).
13. Mercado, N. B. et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus 
macaques. Nature 586, 583-588, https://doi.org/10.1038/s41586-020-2607-z (2020).
14. McMahan, K. et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. 
Nature, https://doi.org/10.1038/s41586-020-03041-6 (2020).
15. Muik, A. et al. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 
vaccine-elicited human sera. Science, https://doi.org/10.1126/science.abg6105 (2021).
16. Wu, K. et al. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants 
from global SARS-CoV-2 variants. bioXriv, https://doi.org/10.1101/2021.01.25.427948 (2021).
17. McCallum, M. et al. N-terminal domain antigenic mapping reveals a site of vulnerability 
for SARS-CoV-2. bioRxiv, https://doi.org/10.1101/2021.01.14.426475 (2021).
18. Suryadevara, N. et al. Neutralizing and protective human monoclonal antibodies 
recognizing the N-terminal domain of the SARS-CoV-2 spike protein. bioRxiv, 
2021.2001.2019.427324, https://doi.org/10.1101/2021.01.19.427324 (2021).
19. Soh, W. T. et al. The N-terminal domain of spike glycoprotein mediates SARS-CoV-2 
infection by associating with L-SIGN and DC-SIGN. bioRxiv, 1-30, https://doi.
org/10.1101/2020.11.05.369264 (2020).
20. Tegally, H. et al. Emergence and rapid spread of a new severe acute respiratory 
syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in 
South Africa. medRxiv, 2020.2012.2021.20248640, https://doi.org/10.1101/ 
2020.12.21.20248640 (2020).
21. Greaney, A. J. et al. Comprehensive mapping of mutations to the SARS-CoV-2 
receptor-binding domain that affect recognition by polyclonal human serum antibodies. 
bioRxiv, 2020.2012.2031.425021, https://doi.org/10.1101/2020.12.31.425021 (2021).
22. Greaney, A. J. et al. Complete mapping of mutations to the SARS-CoV-2 spike receptor- 
binding domain that escape antibody recognition. Cell Host & Microbe (2020).
23. Weisblum, Y. et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein 
variants. Elife 9, e61312, https://doi.org/10.7554/eLife.61312 (2020).
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in 
published maps and institutional affiliations.



























Fig. 1 | Neutralization by first and second dose mRNA vaccine sera against 
wild type and B.1.1.7 Spike mutant SARS-CoV-2 pseudotyped viruses.  
a, Spike in open conformation with a single erect RBD (PDB: 6ZGG) in trimer 
axis vertical view with the locations of mutated residues highlighted in red 
spheres and labelled on the monomer with erect RBD. Vaccine first dose (b-c, 
n=37), second dose (d-e, n=21) and convalescent sera, Conv. (f-g,n=27) against 
WT and B.1.1.7 Spike mutant with N501Y, A570D, ΔH69/V70, Δ144/145, P681H, 
T716I, S982A and D1118H. GMT with s.d presented of two independent 
experiments each with two technical repeats. Wilcoxon matched-pairs signed 
rank test. Two-tailed p-values ** <0.01, ***<0.001, **** <0.0001, ns not 
significant. No adjustment for multiple comparisons. HS – human AB serum 
control. Limit of detection for 50% neutralization set at 10. GMT: geometric 
mean titre for 50% neutralization.




























Fig. 2 | E484K appearing in background of B.1.1.7 with evidence of 
transmission. a. Representation of Spike RBM:ACE2 interface (PDB: 6M0J) 
with residues E484, N501 and K417 highlighted as spheres coloured by element 
b. Maximum likelihood phylogeny of a subset of sequences from the United 
Kingdom bearing the E484K mutation (green) and lineage B.1.1.7 (blue), with 
background sequences without RBD mutations in black. As of 11th Feb 2021,  
30 sequences from the B.1.1.7 lineage (one cluster of 25 at top of phylogenetic 
tree) have acquired the E484K mutation (red). c. Sequence accumulation over 
time in GISAID for UK sequences with B.1.1.7 and E484K. RBD – receptor 
binding domain; NTD – N terminal domain.



























Fig. 3 | Neutralization potency of mRNA vaccine sera and convalescent sera 
(pre SARS-CoV-2 B.1.1.7) against pseudotyped virus bearing Spike 
mutations in the B1.1.7 lineage with and without E484K in the receptor 
binding domain (all In Spike D614G background). a, Example neutralization 
curves for vaccinated individuals. Data points represent mean of technical 
replicates with standard error and are representative of two independent 
experiments (b-g). 50% neutralisation titre for each virus against sera derived 
(b,c, n=37) following first vaccination (d,e, n=21) following second vaccination 
and (f,g, n=20) convalescent sera (CS) expressed as fold change relative to WT. 
Data points are mean fold change of technical replicates and are representative 
of two independent experiments. Central bar represents mean with outer bars 
representing s.d. Error bars for negative values are not shown. Paired T-test. 
Two-tailed p-values *<0.05, **<0.01, ****<0.0001; ns not significant. Limit of 
detection for 50% neutralization set at 10.




























Fig. 4 | Neutralization and binding by a panel of NTD- and RBD-specific 
mAbs against WT, B.1.1.7 and RBD mutant SARS-CoV-2 viruses.  
a, Neutralization of WT D614G (black), B.1.1.7 (blue) and a triple mutant (TM, 
carrying RBD mutations K417N/E484K/N501Y) (red) pseudotyped SARS-CoV-
2-MLVs by 3 selected mAbs (S2E12, S2X333 and S2H14) from one representative 
experiment. Shown is the mean ± s.d. of 2 technical replicates. b, Neutralization 
of WT (D614G), B.1.1.7 and TM SARS-CoV-2-MLVs by 60 mAbs targeting NTD 
(n=10), RBM (n=31) and non-RBM sites in the RBD (n=19). Shown are the mean 
IC50 values (ng/ml) of n=2 independent experiments. c-e, Neutralization 
shown as mean IC50 values (upper panel) and mean fold change of B.1.1.7 (blue) 
or TM (red) relative to WT (lower panel) of NTD (c), RBM (d) and non-RBM (e) 
mAbs. Upper panel shows mean IC50 values ± s.d from 2 independent 
experiments. Lower panel shows mean fold change ± s.d from 2 independent 
experiments. f-h, Kinetics of binding of mAbs to WT (black), N501Y (blue) and 
E484K (red) RBD as measured by bio-layer interferometry (BLI). Shown in (f) are 
the 4 RBM-targeting mAbs with no reduced binding to N501Y or E484K RBD. 
Area under the curve (AUC) (g) and AUC fold change (h) of 50 mAbs tested 
against WT, N501Y and E484K RBD. mAbs with a >1.3 AUC fold change shown in 
blue and red. mAbs: monoclonal antibodies. NTD: N- terminal domain.




























Participant recruitment and ethics
Participants who had received the first dose of vaccine and individu-
als with COVID-19 (Coronavirus Disease-19) were consented into the 
COVID-19 cohort of the NIHR Bioresource. The study was approved by 
the East of England – Cambridge Central Research Ethics Committee 
(17/EE/0025).
SARS-CoV-2 serology by multiplex particle-based flow 
cytometry (Luminex)
Recombinant SARS-CoV-2 N, S and RBD were covalently coupled to 
distinct carboxylated bead sets (Luminex; Netherlands) to form a 3-plex 
and analyzed as previously described (Xiong et al. 2020). Specific bind-
ing was reported as mean fluorescence intensities (MFI). Linear regres-
sion was used to explore the association between antibody response, 
T cell response and serum neutralisation in Stata 13. The Pearson cor-
relation coefficient was reported.
Generation of S mutants
Amino acid substitutions were introduced into the D614G pCDNA_
SARS-CoV-2_S plasmid as previously described24 using the QuikChange 
Lightening Site-Directed Mutagenesis kit, following the manufacturer’s 
instructions (Agilent Technologies, Inc., Santa Clara, CA). Sequences 
were checked by Sanger sequencing.
Preparation of B.1.1.7 or TM SARS-CoV-2 S glycoprotein- 
encoding-plasmid used to produce SARS-CoV-2-MLV based on over-
lap extension PCR. Briefly, a modification of the overlap extension 
PCR protocol25 was used to introduce the nine mutations of the B.1.1.7 
lineage or the three mutations in TM mutant in the SARS-CoV-2 S 
gene. In a first step, 9 DNA fragments with overlap sequences were 
amplified by PCR from a plasmid (phCMV1, Genlantis) encoding 
the  full-length  SARS-CoV-2 S gene (BetaCoV/Wuhan-Hu-1/2019, 
accession number mn908947). The mutations (del-69/70, del-144, 
N501Y, A570D, D614G, P681H, S982A, T716I and D1118H or K417N, E484K 
and N501Y) were introduced by amplification with primers with simi-
lar Tm. Deletion of the C-terminal 21 amino acids was introduced to 
increase surface expression of the recombinant S26. Next, 3 contiguous 
overlapping fragments were fused by a first overlap PCR (step 2) using 
the utmost external primers of each set, resulting in 3 larger fragments 
with overlapping sequences. A final overlap PCR (step 3) was performed 
on the 3 large fragments using the utmost external primers to amplify 
the full-length S gene and the flanking sequences including the restric-
tion sites KpnI and NotI. This fragment was digested and cloned into 
the expression plasmid phCMV1. For all PCR reactions the Q5 Hot Start 
High fidelity DNA polymerase was used (New England Biolabs Inc.), 
according to the manufacturer’s instructions and adapting the elonga-
tion time to the size of the amplicon. After each PCR step the amplified 
regions were separated on agarose gel and purified using Illustra GFX™ 
PCR DNA and Gel Band Purification Kit (Merck KGaA).
Pseudotype virus preparation
Viral vectors were prepared by transfection of 293T cells by using 
Fugene HD transfection reagent (Promega). 293T cells were transfected 
with a mixture of 11ul of Fugene HD, 1µg of pCDNAD19spike-HA, 1ug of 
p8.91 HIV-1 gag-pol expression vector27,28, and 1.5µg of pCSFLW (express-
ing the firefly luciferase reporter gene with the HIV-1 packaging signal). 
Viral supernatant was collected at 48 and 72h after transfection, filtered 
through 0.45um filter and stored at -80˚C. The 50% tissue culture infec-
tious dose (TCID50) of SARS-CoV-2 pseudovirus was determined using 
Steady-Glo Luciferase assay system (Promega).
Serum/plasma pseudotype neutralization assay
Spike pseudotype assays have been shown to have similar charac-
teristics as neutralisation testing using fully infectious wild type 
SARS-CoV-229. Virus neutralisation assays were performed on 293T 
cell transiently transfected with ACE2 and TMPRSS2 using SARS-CoV-2 
spike pseudotyped virus expressing luciferase30. Pseudotyped virus 
was incubated with serial dilution of heat inactivated human serum 
samples or sera from vaccinees in duplicate for 1h at 37˚C. Virus and 
cell only controls were also included. Then, freshly trypsinized 293T 
ACE2/TMPRSS2 expressing cells were added to each well. Following 
48h incubation in a 5% CO2 environment at 37 °C, luminescence was 
measured using the Steady-Glo or Bright-Glo Luciferase assay system 
(Promega). Neutralization was calculated relative to virus only controls. 
Dilution curves were presented as a mean neutralization with standard 
error of the mean (SEM). ID50 values were calculated in GraphPad Prism. 
The ID50 withing groups were summarised as a geometric mean titre 
and statistical comparison between groups were made with Wilxocon 
ranked sign test. In addition, the impact of the mutations on the neu-
tralising effect of the sera were expressed as fold change (FC) of ID50 
of the wild-type compared to mutant pseudotyped virus. Statistical 
difference in the mean FC between groups was determined using a 
2-tailed t-test.
IFNγ FluoroSpot assays
Frozen PBMCs were rapidly thawed, and the freezing medium was 
diluted into 10ml of TexMACS media (Miltenyi Biotech), centrifuged 
and resuspended in 10ml of fresh media with 10U/ml DNase (Benzonase, 
Merck-Millipore via Sigma-Aldrich), PBMCs were incubated at 37 °C for 
1h, followed by centrifugation and resuspension in fresh media supple-
mented with 5% Human AB serum (Sigma Aldrich) before being counted. 
PBMCs were stained with 2ul of each antibody: anti-CD3-fluorescein 
isothiocyanate (FITC), clone UCHT1; anti-CD4-phycoerythrin (PE), 
clone RPA-T4; anti-CD8a-peridinin-chlorophyll protein - cyanine 5.5 
(PerCP Cy5.5), clone RPA-8a (all BioLegend, London, UK), LIVE/DEAD 
Fixable Far Red Dead Cell Stain Kit (Thermo Fisher Scientific). PBMC 
phenotyping was performed on the BD Accuri C6 flow cytometer. Data 
were analysed with FlowJo v10 (Becton Dickinson, Wokingham, UK). 
1.5 to 2.5 x 105 PBMCs were incubated in pre-coated Fluorospot plates 
(Human IFNγ FLUOROSPOT (Mabtech AB, Nacka Strand, Sweden)) 
in triplicate with peptide mixes specific for Spike, Nucleocapsid and 
Membrane proteins of SARS-CoV-2 (final peptide concentration 1µg/
ml/peptide, Miltenyi Biotech) and an unstimulated and positive control 
mix (containing anti-CD3 (Mabtech AB), Staphylococcus Enterotoxin 
B (SEB), Phytohaemagglutinin (PHA) (all Sigma Aldrich)) at 37 °C in a 
humidified CO2 atmosphere for 48 hours. The cells and medium were 
decanted from the plate and the assay developed following the manu-
facturer’s instructions. Developed plates were read using an AID iSpot 
reader (Oxford Biosystems, Oxford, UK) and counted using AID EliSpot 
v7 software (Autoimmun Diagnostika GmbH, Strasberg, Germany). All 
data were then corrected for background cytokine production and 
expressed as spot forming units (SFU)/Million PBMC or CD3 T cells. 
The association between spike Tcell response, spike specific antibody 
response and serum neutralisation was deterimined using linear regres-
sion and the Pearson correlation coefficient between these variables 
were determined using Stata 13.
Ab discovery and recombinant expression
Human mAbs were isolated from plasma cells or memory B cells of 
SARS-CoV or SARS-CoV-2 immune donors, as previously described31–34. 
Recombinant antibodies were expressed in ExpiCHO cells at 37 °C 
and 8% CO2. Cells were transfected using ExpiFectamine. Transfected 
cells were supplemented 1 day after transfection with ExpiCHO Feed 
and ExpiFectamine CHO Enhancer. Cell culture supernatant was col-
lected eight days after transfection and filtered through a 0.2 µm filter. 
Recombinant antibodies were affinity purified on an ÄKTA xpress FPLC 
device using 5 mL HiTrap™ MabSelect™ PrismA columns followed by 
buffer exchange to Histidine buffer (20 mM Histidine, 8% sucrose, pH 6) 




























MAbs pseudovirus neutralization assay
MLV-based SARS-CoV-2 S-glycoprotein-pseudotyped viruses were 
prepared as previously described (Pinto et al., 2020). HEK293T/17cells 
were cotransfected with a WT, B.1.1.7 or TM SARS-CoV-2 spike 
glycoprotein-encoding-plasmid, an MLV Gag-Pol packaging con-
struct and the MLV transfer vector encoding a luciferase reporter 
using X-tremeGENE HP transfection reagent (Roche) according 
to the manufacturer’s instructions. Cells were cultured for 72 h at 
37 °C with 5% CO2 before harvesting the supernatant. VeroE6 stably 
expressing human TMPRSS2 were cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM) containing 10% fetal bovine serum (FBS), 
1% penicillin–streptomycin (100 I.U. penicillin/mL, 100 µg/mL), 
8 µg/mL puromycin and plated into 96-well plates for 16–24 h. Pseu-
dovirus with serial dilution of mAbs was incubated for 1 h at 37 °C 
and then added to the wells after washing 2 times with DMEM. After 
2–3 h DMEM containing 20% FBS and 2% penicillin–streptomycin was 
added to the cells. Following 48-72 h of infection, Bio-Glo (Promega) 
was added to the cells and incubated in the dark for 15 min before 
reading luminescence with Synergy H1 microplate reader (BioTek). 
Measurements were done in duplicate and relative luciferase units 
were converted to percent neutralization and plotted with a non-linear 
regression model to determine IC50 values using GraphPad PRISM 
software (version 9.0.0).
Antibody binding measurements using bio-layer interferometry 
(BLI)
MAbs (Supplementary Table 1) were diluted to 3 µg/ml in kinetic buffer 
(PBS supplemented with 0.01% BSA) and immobilized on Protein A 
Biosensors (FortéBio). Antibody-coated biosensors were incubated 
for 3 min with a solution containing 5 µg /ml of WT, N501Y or E484K 
SARS-CoV-2 RBD in kinetic buffer, followed by a 3-min dissociation 
step. Change in molecules bound to the biosensors caused a shift in 
the interference pattern that was recorded in real time using an Octet 
RED96 system (FortéBio). The binding response over time was used 
to calculate the area under the curve (AUC) using GraphPad PRISM 
software (version 9.0.0).
Production of SARS-CoV-2 and B.1.1.7 receptor binding domains 
and human ACE2
The SARS-CoV-2 RBD (BEI NR-52422) construct was synthesized by 
GenScript into CMVR with an N-terminal mu-phosphatase signal 
peptide and a C-terminal octa-histidine tag (GHHHHHHHH) and 
an avi tag. The boundaries of the construct are N-328RFPN331 and 
528KKST531-C
35. The B.1.1.7 RBD gene was synthesized by GenScript 
into pCMVR with the same boundaries and construct details with a 
mutation at N501Y. These plasmids were transiently transfected into 
Expi293F cells using Expi293F expression medium (Life Technolo-
gies) at 37 °C 8% CO2 rotating at 150 rpm. The cultures were trans-
fected using PEI cultivated for 5 days. Supernatants were clarified by 
centrifugation (10 min at 4000xg) prior to loading onto a nickel-NTA 
column (GE). Purified protein was biotinylated overnight using BirA 
(Biotin ligase) prior to size exclusion chromatography (SEC) into 
phosphate buffered saline (PBS). Human ACE2-Fc (residues 1-615 
with a C-terminal thrombin cleavage site and human Fc tag) were 
synthesized by Twist. Clarified supernatants were affinity purified 
using a Protein A column (GE LifeSciences) directly neutralized and 
buffer exchanged. The Fc tag was removed by thrombin cleavage in 
a reaction mixture containing 3 mg of recombinant ACE2-FC ecto-
domain and 10 µg of thrombin in 20 mM Tris-HCl pH8.0, 150 mM 
NaCl and 2.5 mM CaCl2.The reaction mixture was incubated at 25 °C 
overnight and re-loaded on a Protein A column to remove uncleaved 
protein and the Fc tag. The cleaved protein was further purified by 
gel filtration using a Superdex 200 column 10/300 GL (GE Life Sci-
ences) equilibrated in PBS.
Protein affinity measurement using bio-layer interferometry
Biotinylated RBD (WT, N501Y, or TM) were immobilized at 5 ng/uL in 
undiluted 10X Kinetics Buffer (Pall) to SA sensors until a load level of 
1.1nm. A dilution series of either monomeric ACE2 or Fab in undiluted 
kinetics buffer starting at 1000-50nM was used for 300-600 seconds to 
determine protein-protein affinity. The data were baseline subtracted 
and the plots fitted using the Pall FortéBio/Sartorius analysis software 
(version 12.0). Data were plotted in Prism.
Phylogenetic analysis
All complete and low coverage excluded SARS-CoV-2 sequences were 
downloaded from the GISAID database (http://gisaid.org/)36 on 11th 
February 2021. All sequences were realigned to the SARS-CoV-2 refer-
ence strain MN908947.3, using MAFFT v7.475 with automatic flavour 
selection and the --keeplength --addfragments options37. Sequences 
were then deduplicated. Major SARS-CoV-2 clade memberships were 
assigned to all sequences using the Nextclade server v0.12 (https://
clades.nextstrain.org/).
Maximum likelihood phylogenetic trees were produced using the 
above curated dataset using IQ-TREE v2.1.238. Evolutionary model 
selection for trees were inferred using ModelFinder39 and trees were 
estimated using the GTR+F+I model with 1000 ultrafast bootstrap 
replicates40. All trees were visualised with Figtree v.1.4.4 (http://tree.
bio.ed.ac.uk/software/figtree/) and manipulated and coloured with 
ggtree v2.2.4. Phylogenies were rooted on the SARS-CoV-2 reference 
sequence (MN908947.3) and nodes arranged in descending order.
Statistical analysis
Linear regression was used to explore the association between antibody 
response, T cell response and serum neutralisation in Stata 13. The 
Pearson correlation coefficient was reported.
Neutralisation data analysis
Neutralization was calculated relative to virus only controls. Dilution 
curves were presented as a mean neutralization with standard error 
of the mean (SEM). IC50 values were calculated in GraphPad Prism. 
The inhibitory dilution (ID50) within groups were summarised as a 
geometric mean titre and statistical comparison between groups were 
made with Wilxocon ranked sign test. In addition, the impact of the 
mutations on the neutralising effect of the sera were expressed as fold 
change of ID50 of the wild-type compared to mutant pseudotyped virus. 
Statistical difference in the mean FC between groups was determined 
using a 2-tailed t-test.
For antibody level
IFNγ FluoroSpot assay data analysis. The association between 
spike Tcell response, spike specific antibody response and serum 
neutralisation was determined using linear regression and the Pear-
son correlation coefficient between these variables were determined 
using Stata 13.
Reporting summary
Further information on research design is available in the Nature 
Research Reporting Summary linked to this paper.
Data availability
The neutralization and BLI data shown in Fig. 4 and Extended Data 
Figs. 6–8 can be found in Source Data for Fig. 4. All sequences are 
publicly available and were downloaded from http://gisaid.org. Dedu-
plicated and subsampled data are freely available at https://github.
com/StevenKemp/sequence_files/blob/main/vaccinepaper/with_back-
ground_subsampled_deduped_aligned_UKonly_484_vui.fasta.gz. Other 
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Extended Data Fig. 1 | Immune responses three weeks after first dose of 
Pfizer SARS-CoV-2 vaccine BNT162b2. a, N= 25, serum IgG responses against 
N protein, Spike and the Spike Receptor Binding Domain (RBD) from first 
vaccine participants (green), recovered COVID-19 cases (red), 3 convalescent 
plasma units and healthy controls (grey) as measured by a flow cytometry 
based Luminex assay. MFI, mean fluorescence intensity. Geometric mean titre 
(GMT with standard deviation (s.d) of two technical repeats presented. b, N=25, 
relationship between serum IgG responses as measured by flow cytometry and 
serum neutralisation ID50. c, N=24, relationship between serum neutralisation 
ID50 and T cell responses against SARS-CoV-2 by IFN gamma ELISpot. SFU: spot 
forming units. d, N=23, relationship between serum IgG responses and T cell 
responses. Simple linear regression is presented with Pearson correlation (r), 



























Extended Data Fig. 2 | Neutralization by first dose BNT162b2 vaccine and 
convalescent sera against wild type and mutant (N501Y, A570D, ΔH69/V70) 
SARS-CoV-2 pseudotyped viruses. (a-b) Vaccine sera dilution for 50% 
neutralization against WT and Spike mutant with N501Y, A570D, ΔH69/V70. 
Geometric mean titre (GMT) + s.d of two independent experiments with two 
technical repeats presented. Wilcoxon matched-pairs signed rank test. 
Two-tailed p-values ***<0.001, ns not significant. No adjustment for multiple 
comparisons. (c-d) Convalescent sera dilution for 50% neutralization against 
WT and Spike mutant with N501Y, A570D, ΔH69/V70. GMT + s.d of 
representative experiment with two technical repeats presented.  
e, Representative curves of convalescent serum log10 inverse dilution against % 
neutralization for WT v N501Y, A570D, ΔH69/V70. Where a curve is shifted to 
the right this indicates the virus is less sensitive to the neutralizing antibodies 
in the serum. Data are means of technical replicates and error bars represent 
standard error of the mean. Data are representative of 2 independent 




























Extended Data Fig. 3 | Representative neutralization curves of BNT162b2 
vaccine sera against pseudovirus virus bearing eight Spike mutations 
present in B.1.1.7 versus wild type (all In Spike D614G background). 
Indicated is serum log10 inverse dilution against % neutralization. Where a 
curve is shifted to the right this indicates the virus is less sensitive to the 
neutralizing antibodies in the serum. Data are for first dose of vaccine (D1). 
Data are representative of two independent experiments each with two 
technical replicates. Data points are means of technical replicates and error 
bars represent standard error of the mean. Limit of detection for 50% 



























Extended Data Fig. 4 | Representative neutralization curves of convalescent 
sera against wild type and B.1.1.7 Spike mutant SARS-CoV-2 pseudoviruses. 
Indicated is serum log10 inverse dilution against % neutralization. Where a curve 
is shifted to the right this indicates the virus is less sensitive to the neutralizing 
antibodies in the serum. Data are representative of two independent 
experiments each with two technical replicates. Data points are means of 
technical replicates and error bars represent standard error of the mean.  




























Extended Data Fig. 5 | Neutralisation potency of mRNA vaccine sera and 
convalescent sera (pre SARS-CoV-2 B.1.1.7) against pseudotyped virus 
bearing Spike mutations in the B.1.1.7 lineage with and without E484K in 
the receptor binding domain (all In Spike D614G background). Vaccine first 
dose (a, n=37), second dose (b, n=21) and convalescent sera, Conv. (c=27) 
against WT, B.1.1.7 Spike mutant with N501Y, A570D, ΔH69/V70, Δ144/145, 
P681H, T716I, S982A and D1118H and B.1.1.7 with E484K. GMT with s.d 
representative of two independent experiments each with two technical 
repeats are presented. Wilcoxon matched-pairs signed rank test p-values * 
<0.05, ** <0.01, ***<0.001, **** <0.0001, ns not significant. GMT: geometric 



























Extended Data Fig. 6 | Neutralisation of WT (D614G), B.1.1.7 and TM (N501Y, 
E484K, K417N) SARS-CoV-2 Spike pseudotyped virus by a panel of 
57 monoclonal antibodies (mAbs). a-c, Neutralisation of WT (black), B.1.1.7 
(blue) and TM (red) SARS-CoV-2-MLV by 9 NTD-targeting (a), 29 RBM-targeting 
(b) and 19 non-RBM-targeting (c) mAbs. Data from one representative 




























Extended Data Fig. 7 | Kinetics of binding to WT and N501Y SARS-CoV-2 RBD 
of 43 RBD-specific mAbs. a-b, Binding to WT (black) and N501Y (blue) RBD by 
22 RBM-targeting (a) and 21 non-RBM-targeting (b) mAbs. An antibody of 




























Extended Data Fig. 8 | Kinetics of binding to WT and E484K SARS-CoV-2 
RBD of 46 RBD-specific mAbs. a-b, Binding to WT (black) and E484K (red) 
RBD by 27 RBM-targeting (a) and 19 non-RBM-targeting (b) mAbs. An antibody 





























Extended Data Fig. 9 | Binding of human ACE2 to SARS-CoV-2 WT, N501Y, 
TM (N501Y, E484K, K417N) RBDs. a-b, BLI binding analysis of the human ACE2 
ectodomain (residues 1-615) to immobilized SARS-CoV-2 WT RBD (a) and B.1.1.7 
RBD (c). Black lines correspond to a global fit of the data using a 1:1 binding 



























Extended data Table 1 | Kinetic analysis of human ACE2 binding to SARS-CoV-2 Wuhan-1, N501Y and N501Y/ E484K/ K417N 
(TM) RBDs by biolayer interferometry
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Data collection Sequences were obtained from GISAID using the search parameters defined in the methods section. Monoclonal antibody binding data were 
collected with Octet RED96 system (FortéBio). Monoclonal antibody neutralization data (luminescence) were collected with Synergy H1 
microplate reader (BioTek). Sera neutralising antibody data were read on a Glomax luminometer (Promega). 
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Antibodies used The source of monoclonal antibodies used in this study is described in Extended Data Table 1 and in the Method session.
Validation The monoclonal antibodies were validated by binding and neutralization assays as described in the references of Extended Data 
Table 1.
Eukaryotic cell lines
Policy information about cell lines
Cell line source(s) HEK 293T and ExpiCHO cells were used for transfection work to produce pseudoviruses and mAbs, respectively.  
Authentication No cell lines used were authenticated. No new cell lines were generated.
Mycoplasma contamination All cell lines used were tested (by PCR) and were mycoplasma free.
Commonly misidentified lines
(See ICLAC register)
No commonly misidentified lines were used in this study.
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Recruitment Participants were consented into the COVID-19 cohort of the NIHR Bioresource. Consecutive individuals were enrolled 
without exclusion.
Ethics oversight The study was approved by the East of England – Cambridge Central Research Ethics Committee (17/EE/0025).
Note that full information on the approval of the study protocol must also be provided in the manuscript.
